|
KR20200071075A
|
|
Compositions and methods for treating brain damage
|
|
EP3122743A1
|
|
Compositions and methods for treating neurodegenerative diseases
|
|
AU2013206201A1
|
|
Beta-lactamylalkanoic acids for treating premenstrual disorders
|
|
EP2587919A1
|
|
Methods for treating post traumatic stress disorder
|
|
WO2008034032A2
|
|
Beta-lactam cannabinoid receptor modulators
|
|
WO2007109615A2
|
|
β -LACTAMYL VASOPRESSIN V2 ANTAGONISTS
|
|
WO2007109098A2
|
|
HYDROXY AND KETO-SUBSTITUTED β-LACTAMYL ALKANEDIOIC ACIDS
|
|
US2008280870A1
|
|
Beta-lactamyl phenylalanine, cysteine, and serine vasopressin antagonists
|
|
CN104922117A
|
|
Beta-lactamylalkanoic acids for treating premenstrual disorders
|
|
CN101208010A
|
|
Beta-lactamylalkanoic acids for treating premenstrual disorders
|
|
MY165578A
|
|
Beta-lactamyl vasopressin v1a antagonists
|
|
CN103288815A
|
|
Beta-lactamyl vasopression V1a antagonists
|
